Zyn Class Action Lawsuit: Timeline and Major Allegations

Philip Morris's New Nicotine Product and Youth Addiction Concerns

Philip Morris International's 2022 acquisition of Swedish Match for $16 billion signaled a strategic bet that smokeless nicotine pouches represented the future of nicotine delivery. Zyn (Swedish Match's flagship product) already dominated the U.S. nicotine pouch market with roughly 75% market share. Under PMI's stewardship, Zyn's distribution and marketing investment has accelerated dramatically, raising the stakes in litigation that alleges the product was designed and marketed to create nicotine addiction in a new generation of users who would not otherwise have used tobacco products.

The class action complaint (filed by plaintiff firms with extensive tobacco litigation experience) frames the case around Philip Morris's own documented history of marketing tactics. Internal documents from the original tobacco litigation established that major manufacturers knew nicotine was addictive and deliberately engineered products and marketing to maximize addiction uptake. Plaintiffs allege PMI has applied this institutional knowledge to Zyn, creating a "starter nicotine product" with flavor profiles, social media marketing, and user experience design calibrated to attract non-tobacco users, particularly young adults.

The TikTok and Influencer Marketing Strategy

The most legally significant marketing allegation involves Zyn's social media presence. The #Zyn and #ZynLife hashtags accumulated hundreds of millions of views on TikTok, where the demographic skews heavily toward users 18-24 (and younger). Swedish Match and PMI worked with influencers whose follower demographics included substantial proportions of minors, a fact that plaintiff attorneys argue either was known or should have been known given that platforms provide demographic data to advertising partners. Related: Zyn individual product claims.

The FDA's 2024 denial of Zyn's premarket tobacco product applications specifically flagged inadequate youth access prevention as a basis for denial. This regulatory finding is highly probative: the FDA concluded that Zyn's marketing strategy did not adequately prevent minors from accessing and using the product, supporting the class action's central factual allegation. The Senate Commerce Committee's January 2024 hearing, at which PMI's CEO testified about Zyn marketing practices, further established the public record underpinning the litigation.

The Nicotine Addiction as Injury Theory

Courts have generally recognized nicotine addiction as a cognizable injury supporting both medical monitoring claims and personal injury damages. The first-time nicotine user who becomes addicted through Zyn use, having never been addicted to cigarettes, smokeless tobacco, or other nicotine products, has suffered a quantifiable harm: the cost of addiction treatment, reduced earning capacity if addiction-related health issues develop, and the diminished quality of life associated with dependence on an addictive substance.

The class definition in the Zyn litigation focuses on this population: adults and minors who first became regular nicotine users through Zyn rather than having pre-existing nicotine dependence who transitioned to pouches. This distinction is important for causation: if the class member was already addicted to cigarettes when they switched to Zyn, the causation theory becomes more complex. The strongest claims involve individuals who used Zyn as their first and only nicotine product and subsequently developed dependence. Related: individual Zyn consumer claims.

Who Can Join the Zyn Class Action?

The class encompasses individuals who (1) began using Zyn or similar nicotine pouches without prior nicotine dependence, (2) developed nicotine dependence attributable to Zyn use, and (3) suffered measurable harm including addiction treatment costs or documented health consequences. Government entity sub-classes cover states and municipalities with Medicaid or healthcare costs attributable to Zyn-related addiction treatment. Youth plaintiff sub-classes cover minors who accessed and became addicted to Zyn despite being below the legal purchase age of 21.

How to File a Claim: Step-by-Step

Once a settlement is approved, the process for filing a claim is typically as follows: (1) Visit the official settlement website designated by the court-appointed claims administrator. (2) Complete the online or paper claim form, providing your contact information, purchase history, and any required documentation. (3) Submit before the claims deadline, late claims are almost never accepted. (4) Wait for the claims administrator to review and verify your submission. (5) Receive your settlement check or electronic payment once the court grants final approval and any appeals are resolved.

Be wary of third-party services that charge fees to "help" you file a class action claim. Legitimate class action claim forms are always free to submit directly through the official settlement administrator's website.

How to File a Claim or Get Help

If you believe you qualify based on the eligibility criteria outlined above, the next step is a free consultation with an experienced attorney who handles this case type. Most plaintiff-side attorneys offer no-cost initial evaluations and work on contingency, meaning you pay nothing unless your case results in a recovery. Bring any relevant documentation to your consultation: receipts, medical records, correspondence, or any evidence of the harm you experienced.

To stay current on case developments, claim deadlines, and settlement news, bookmark this page and subscribe to the LawsuitWatch newsletter. We update our coverage as new court filings, settlement announcements, and eligibility changes are made public.